Journal of Pathology and Translational Medicine10.4132/jptm.2019.11.03202054134-44HER2 status in breast cancer: changes in guidelines and complicating factors for interpretationSoomin Ahn, Ji Won Woo, Kyoungyul Lee, So Yeon Park,,
Breast Cancer Research10.1186/bcr1783200795Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 statusTanja Fehm, Sven Becker, Silke Duerr-Stoerzer, Karl Sotlar, Volkmar Mueller, Diethelm Wallwiener, Nancy Lane, Erich Solomayer, Jonathan Uhr,,
The Breast10.1016/s0960-9776(12)70039-5201221S10PO27 HER2 and steroid receptor status in pregnancy-associated breast cancerM. Litwiniuk, E. Breborowicz,
Breast Diseases: A Year Book Quarterly10.1016/s1043-321x(07)80043-9200718163-641–33 Predicting Tissue HER2 Status Using Serum HER2 Levels in Patients with Metastatic Breast CancerM.Z. Gilcrease,
Human Pathology10.1016/j.humpath.2004.11.0102005363250-261Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelinesDavid G. Hicks, Raymond R. Tubbs,
The Open Biomarkers Journal10.2174/1875318302010010038202010138-46New Insights to Reshape the Management of Patients with Metastatic Breast Cancer - Focus on Overcoming Challenges in HER2 Status InterpretationKatarzyna Rygiel,,
Her2-Positive Breast Cancer10.1016/b978-0-323-58122-6.00004-0201963-74HER2-Positive Breast CancerSarah Sammons, Kimberly Blackwell,
Her2-Positive Breast Cancer10.1016/b978-0-323-58122-6.00014-32019231-237Biosimilars for HER2-Positive Breast CancerHope S. Rugo,
Her2-Positive Breast Cancer10.1016/b978-0-323-58122-6.00012-x2019179-212Novel Non–HER2-targeted Therapies in HER2+ Breast CancerMarina N. Sharifi, Ruth M. O'Regan,
Breast Cancer Research10.1186/bcr33352013151How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?Nadine Norton, Edith A Perez,,